Review of the complications associated with treatment of oropharyngeal cancer: A guide for the dental practitioner

Quintessence International

Volumn 44, Issue 3, 2013, Pages 267-279

  Turner, Lena ^a   Mupparapu, Muralidhar ^a,b   Akintoye, Sunday O ^b  

^a Department of Oral Medicine ^*  (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cancer; Chemotherapy; Complications; Osteoradionecrosis; Radiotherapy; Xerostomia

Indexed keywords

ANTINEOPLASTIC AGENT;

ADVERSE DRUG REACTION; COMPLICATION; DENTAL CARIES; DENTAL PROCEDURE; HUMAN; JAW DISEASES; MOUTH DISEASES; NEURALGIA; OROPHARYNGEAL NEOPLASMS; OSTEORADIONECROSIS; QUALITY OF LIFE; RADIOTHERAPY; STOMATITIS; SURVIVAL RATE; TOOTH DISEASES; XEROSTOMIA; BONE NECROSIS; JAW DISEASE; MOUTH DISEASE; OROPHARYNX TUMOR; REVIEW; TOOTH DISEASE;

ANTINEOPLASTIC AGENTS; DENTAL CARE FOR CHRONICALLY ILL; DENTAL CARIES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ESTHETICS, DENTAL; HUMANS; JAW DISEASES; MOUTH DISEASES; NEURALGIA; OROPHARYNGEAL NEOPLASMS; OSTEORADIONECROSIS; QUALITY OF LIFE; RADIOTHERAPY; STOMATITIS; SURVIVAL RATE; TOOTH DISEASES; XEROSTOMIA;

EID: 84879913522     PISSN: 00336572     EISSN: None     Source Type: Journal    
DOI: 10.3290/j.qi.a29050     Document Type: Article

References (70)

1. Moore SR, Johnson NW, Pierce AM, Wilson DF. The epidemiology of mouth cancer: a review of global incidence. Oral Dis 2000;6: 65-74.
2. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2008. Based on November 2010 SEER data submission, posted to the SEER web site, 2011. Bethesda, MD: National Cancer Institute, 2011.
3. Edwards BK, Howe HL, Ries LA, et al. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer 2002;94: 2766-2792.
4. McDowell JD. An overview of epidemiology and common risk factors for oral squamous cell carcinoma. Otolaryngol Clin North Am 2006;39: 277-294.
5. Brennan JA, Boyle JO, Koch WM, et al. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med 1995;332: 712-717.
6. Brooks PJ, Theruvathu JA. DNA adducts from acetaldehyde: implications for alcohol-related carcinogenesis. Alcohol 2005;35: 187-193.
7. Castellsague X, Quintana MJ, Martinez MC, et al. The role of type of tobacco and type of alcoholic beverage in oral carcinogenesis. Int J Cancer 2004;108: 741-749.
8. Silverman S Jr. Demographics and occurrence of oral and pharyngeal cancers. The outcomes, the trends, the challenge. J Am Dent Assoc 2001;132(Suppl): 7S-11S.
9. Schantz SP, Yu GP. Head and neck cancer incidence trends in young Americans, 1973-1997, with a special analysis for tongue cancer. Arch Otolaryngol Head Neck Surg 2002;128: 268-274.
10. Kreimer AR, Clifford GM, Snijders PJ, et al. HPV16 semiquantitative viral load and serologic biomarkers in oral and oropharyngeal squamous cell carcinomas. Int J Cancer 2005;115: 329-332.
11. Rudat V, Wannenmacher M. Role of multimodal treatment in oropharynx, larynx, and hypopharynx cancer. Semin Surg Oncol 2001;20: 66-74.
12. Sonis ST, Sonis AL, Lieberman A. Oral complications in patients receiving treatment for malignancies other than of the head and neck. J Am Dent Assoc 1978;97: 468-472.
13. Myers RA, Marx RE. Use of hyperbaric oxygen in postradiation head and neck surgery. NCI Monogr 1990: 151-157.
14. Marx RE. Osteoradionecrosis: a new concept of its pathophysiology. J Oral Maxillofac Surg 1983;41: 283-288.
15. Fischer DJ, Epstein JB. Management of patients who have undergone head and neck cancer therapy. Dent Clin North Am 2008;52: 39-60, viii.
16. Arias de la Vega F, Contreras J, de Las Heras M, et al. Erlotinib and chemoradiation in patients with surgically resected locally advanced squamous cell carcinoma of the head and neck: a GICOR phase I trial. Ann Oncol 2012;23: 1005-1009.
17. Sonis ST. Mucositis as a biological process: a new hypothesis for the development of chemotherapyinduced stomatotoxicity. Oral Oncol 1998;34: 39-43.
18. Watters AL, Epstein JB, Agulnik M. Oral complications of targeted cancer therapies: a narrative literature review. Oral Oncol 2011;47: 441-448.
19. Sonis ST, Costa JW Jr. Complications of Cancer and its Treatment. In: Holland JF, Frei E (eds). Cancer Medicine. Hamilton, Ontario: BC Decker, 2003.
20. Nishimura N, Nakano K, Ueda K, et al. Prospective evaluation of incidence and severity of oral mucositis induced by conventional chemotherapy in solid tumors and malignant lymphomas. Support Care Cancer 2012;20: 2053-2059.
21. Mosel DD, Bauer RL, Lynch DP, Hwang ST. Oral complications in the treatment of cancer patients. Oral Dis 2011;17: 550-559.
22. Epstein JB, Klasser GD. Emerging approaches for prophylaxis and management of oropharyngeal mucositis in cancer therapy. Expert Opin Emerg Drugs 2006;11: 353-373.
23. Cascinu S, Fedeli A, Fedeli SL, Catalano G. Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil-induced stomatitis. Eur J Cancer B Oral Oncol 1994;30B: 234-236.
24. Ryu JK, Swann S, LeVeque F, et al. The impact of concurrent granulocyte macrophage-colony stimulating factor on radiation-induced mucositis in head and neck cancer patients: a double-blind placebocontrolled prospective phase III study by Radiation Therapy Oncology Group 9901. Int J Radiat Oncol Biol Phys 2007;67: 643-650.
25. Hejna M, Kostler WJ, Raderer M, et al. Decrease of duration and symptoms in chemotherapy-induced oral mucositis by topical GM-CSF: results of a prospective randomised trial. Eur J Cancer 2001;37: 1994-2002.
26. Epstein JB, Silverman S Jr, Paggiarino DA, et al. Benzydamine HCl for prophylaxis of radiationinduced oral mucositis: results from a multicenter, randomized, double-blind, placebo-controlled clinical trial. Cancer 2001;92: 875-885.
27. Akintoye SO, Brennan MT, Graber CJ, et al. A retrospective investigation of advanced periodontal disease as a risk factor for septicemia in hematopoietic stem cell and bone marrow transplant recipients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002;94: 581-588.
28. Lerman MA, Laudenbach J, Marty FM, Baden LR, Treister NS. Management of oral infections in cancer patients. Dent Clin North Am 2008;52: 129-153, ixs.
29. Ship JA, Vissink A, Challacombe SJ. Use of prophylactic antifungals in the immunocompromised host. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;103(Suppl 6): e1-14.
30. Epstein JB, Gorsky M, Caldwell J. Fluconazole mouthrinses for oral candidiasis in postirradiation, transplant, and other patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002;93: 671-675.
31. Schubert MM. Oral manifestations of viral infections in immunocompromised patients. Curr Opin Dent 1991;1: 384-397.
32. Woo SB, Challacombe SJ. Management of recurrent oral herpes simplex infections. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;103(Suppl 12): e11-18.
33. Epstein JB, Stevenson-Moore P. Periodontal disease and periodontal management in patients with cancer. Oral Oncol 2001;37: 613-619.
34. Lee MK, Nalliah RP, Kim MK, Elangovan S, Allareddy V, Kumar-Gajendrareddy P. Prevalence and impact of complications on outcomes in patients hospitalized for oral and oropharyngeal cancer treatment. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011;112: 581-591.
35. Kielbassa AM, Hinkelbein W, Hellwig E, Meyer-Luckel H. Radiation-related damage to dentition. Lancet Oncol 2006;7: 326-335.
36. Jongebloed WL, Gravenmade EJ, Retief DH. Radiation caries. A review and SEM study. Am J Dent 1988;1: 139-146.
37. Fujita M, Tanimoto K, Wada T. Early radiographic changes in radiation bone injury. Oral Surg Oral Med Oral Pathol 1986;61: 641-644.
38. Chambers MS, Posner M, Jones CU, et al. Cevimeline for the treatment of postirradiation xerostomia in patients with head and neck cancer. Int J Radiat Oncol Biol Phys 2007;68: 1102-1109.
39. Galler C, Epstein JB, Guze KA, Buckles D, Stevenson-Moore P. The development of osteoradionecrosis from sites of periodontal disease activity: report of 3 cases. J Periodontol 1992;63: 310-316.
40. Epstein JB, Lunn R, Le N, Stevenson-Moore P. Periodontal attachment loss in patients after head and neck radiation therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998;86: 673-677.
41. Reuther T, Schuster T, Mende U, Kubler A. Osteoradionecrosis of the jaws as a side effect of radiotherapy of head and neck tumour patients: a report of a thirty year retrospective review. Int J Oral Maxillofac Surg 2003;32: 289-295.
42. Vissink A, Jansma J, Spijkervet FK, Burlage FR, Coppes RP. Oral sequelae of head and neck radiotherapy. Crit Rev Oral Biol Med 2003;14: 199-212.
43. Sweeney MP, Bagg J, Baxter WP, Aitchison TC. Clinical trial of a mucin-containing oral spray for treatment of xerostomia in hospice patients. Palliat Med 1997;11: 225-232.
44. Jabbari S, Kim HM, Feng M, et al. Matched casecontrol study of quality of life and xerostomia after intensity-modulated radiotherapy or standard radiotherapy for head-and-neck cancer: initial report. Int J Radiat Oncol Biol Phys 2005;63: 725-731.
45. Bardet E, Martin L, Calais G, et al. Subcutaneous compared with intravenous administration of amifostine in patients with head and neck cancer receiving radiotherapy: final results of the GORTEC2000-02 phase III randomized trial. J Clin Oncol 2011;29: 127-133.
46. Sasse AD, Clark LG, Sasse EC, Clark OA. Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis. Int J Radiat Oncol Biol Phys 2006;64: 784-791.
47. Wasserman TH, Brizel DM, Henke M, et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for headand- neck cancer: 2-year follow-up of a prospective, randomized, phase III trial. Int J Radiat Oncol Biol Phys 2005;63: 985-990.
48. Gornitsky M, Shenouda G, Sultanem K, et al. Doubleblind randomized, placebo-controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004;98: 45-52.
49. Atkinson JC, Grisius M, Massey W. Salivary hypofunction and xerostomia: diagnosis and treatment. Dent Clin North Am 2005;49: 309-326.
50. Garcia MK, Chiang JS, Cohen L, et al. Acupuncture for radiation-induced xerostomia in patients with cancer: a pilot study. Head Neck 2009;31: 1360-1368.
51. Marx RE, Johnson RP. Studies in the radiobiology of osteoradionecrosis and their clinical significance. Oral Surg Oral Med Oral Pathol 1987;64: 379-390.
52. Epstein J, van der Meij E, McKenzie M, Wong F, Lepawsky M, Stevenson-Moore P. Postradiation osteonecrosis of the mandible: a long-term followup study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997;83: 657-662.
53. O’Dell K, Sinha U. Osteoradionecrosis. Oral Maxillofac Surg Clin North Am 2011;23: 455-464.
54. Katsura K, Sasai K, Sato K, Saito M, Hoshina H, Hayashi T. Relationship between oral health status and development of osteoradionecrosis of the mandible: a retrospective longitudinal study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;105: 731-738.
55. Shaw RJ, Butterworth C. Hyperbaric oxygen in the management of late radiation injury to the head and neck. Part II: prevention. Br J Oral Maxillofac Surg 2011;49: 9-13.
56. D’Souza J, Goru J, Goru S, Brown J, Vaughan ED, Rogers SN. The influence of hyperbaric oxygen on the outcome of patients treated for osteoradionecrosis: 8 year study. Int J Oral Maxillofac Surg 2007;36: 783-787.
57. Thom SR, Bhopale VM, Velazquez OC, Goldstein LJ, Thom LH, Buerk DG. Stem cell mobilization by hyperbaric oxygen. Am J Physiol Heart Circ Physiol 2006;290: H1378-1386.
58. Marchettini P, Formaglio F, Lacerenza M. Iatrogenic painful neuropathic complications of surgery in cancer. Acta Anaesthesiol Scand 2001;45: 1090-1094.
59. Cata JP, Weng HR, Lee BN, Reuben JM, Dougherty PM. Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy. Minerva Anestesiol 2006;72: 151-169.
60. Clark GT, Ram S. Orofacial pain and neurosensory disorders and dysfunction in cancer patients. Dent Clin North Am 2008;52: 183-202, ix-xs.
61. Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol 2010;9: 807-819.
62. Buchbinder D, Currivan RB, Kaplan AJ, Urken ML. Mobilization regimens for the prevention of jaw hypomobility in the radiated patient: a comparison of three techniques. J Oral Maxillofac Surg 1993;51: 863-867.
63. Stubblefield MD, Manfield L, Riedel ER. A preliminary report on the efficacy of a dynamic jaw opening device (dynasplint trismus system) as part of the multimodal treatment of trismus in patients with head and neck cancer. Arch Phys Med Rehabil 2010;91: 1278-1282.
64. Clark GT. The management of oromandibular motor disorders and facial spasms with injections of botulinum toxin. Phys Med Rehabil Clin N Am 2003;14: 727-748.
65. Nelson GM. Biology of taste buds and the clinical problem of taste loss. Anat Rec 1998;253: 70-78.
66. Halyard MY, Jatoi A, Sloan JA, Bearden JD, 3rd, Vora SA, Atherton PJ, et al. Does zinc sulfate prevent therapy-induced taste alterations in head and neck cancer patients? Results of phase III double-blind, placebo-controlled trial from the North Central Cancer Treatment Group (N01C4). Int J Radiat Oncol Biol Phys 2007;67: 1318-1322.
67. Ripamonti C, Zecca E, Brunelli C, et al. A randomized, controlled clinical trial to evaluate the effects of zinc sulfate on cancer patients with taste alterations caused by head and neck irradiation. Cancer 1998;82: 1938-1945.
68. Cubukcu CE, Sevinir B, Ercan I. Disturbed dental development of permanent teeth in children with solid tumors and lymphomas. Pediatr Blood Cancer 2012;58: 80-84.
69. Aguiar GP, Jham BC, Magalhaes CS, Sensi LG, Freire AR. A review of the biological and clinical aspects of radiation caries. J Contemp Dent Pract 2009;10: 83-89.
70. Schubert MM, Peterson DE. Oral complications of hematopoietic cell transplantation. In: Appelbaum FR, Forman SJ, Negrin RS, Blume KG (eds). Thomas’ Hematopoietic cell transplantation: Stem cell transplantation. Oxford, UK: Wiley-Blackwell, 2009: 1589-1607.